Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04073849 · ClinicalTrials.gov registry record · Early Phase 1

CD71 in Dried Blood Spots in Healthy Males

A Early Phase 1 study of Healthy Athletes, sponsored by Sports Medicine Research and Testing Laboratory.

Completed
Registry status
Early Phase 1
Development phase
24
Enrollment target
1
Study location

NCT04073849 is a Early Phase 1 study of Healthy Athletes that has completed, run by Sports Medicine Research and Testing Laboratory. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04073849, a Early Phase 1 study of Healthy Athletes, has completed, sponsored by Sports Medicine Research and Testing Laboratory.

COMPLETED
Registry status
Early Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Understand the effect of recombinant EPO (rEPO) boosting and microdosing on the hematological module of the Athlete Biological Passport (ABP) * Measure the change in CD71 longitudinally in subjects from both cohorts * Assess whether rEPO administration can be detected in a dried blood spot (DBS) using recent advances in analytical methodologies * Compare windows of rEPO detection using both Athlete Biological Passport models and direct detection using analytical methods in urine, blood, and DBS

Conditions Studied

Interventions

  • OTHER Normal Saline
  • DRUG EPOGEN® (epoetin alfa)

Study Locations (1)

Utah

  • Sports Medicine Research and Testing Laboratory - Salt Lake City

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2019-07-15
Est. Completion 2020-12-01
Phase Early Phase 1

What the Registry Record Tells You About NCT04073849

The ClinicalTrials.gov registry entry for NCT04073849 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sports Medicine Research and Testing Laboratory, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Athletes appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.

NCT04073849 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT04073849 about?

NCT04073849 is a clinical study titled "CD71 in Dried Blood Spots in Healthy Males". Understand the effect of recombinant EPO (rEPO) boosting and microdosing on the hematological module of the Athlete Biological Passport (ABP) * Measure the change in CD71 longitudinally in subjects from both cohorts * Assess whether rEPO administration can be detected in a dried blood spot (DBS) us...

What is the current status of trial NCT04073849?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2019-07-15. Estimated completion is 2020-12-01.

What conditions does trial NCT04073849 study?

This clinical trial studies the following conditions: Healthy Athletes.

What interventions are being tested in trial NCT04073849?

The interventions under investigation include: Normal Saline (OTHER), EPOGEN® (epoetin alfa) (DRUG).

Who is sponsoring clinical trial NCT04073849?

This trial is sponsored by Sports Medicine Research and Testing Laboratory, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04073849 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.